A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-01-11
Target enrollment:
Participant gender:
Summary
To determine the activity of lenalidomide in the treatment of pediatric subjects with
relapsed/refractory acute myeloid leukemia (AML) (with second or greater relapse or
refractory to at least 2 prior induction attempts) measured by morphological complete
response defined as either a CR or CRi within the first 4 cycles of treatment.